Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...

As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...

New data identify age, anti-β2GP1 antibodies, and low C3 as key risk factors for cerebral small vessel disease in systemic ...

Subcutaneous anifrolumab (Saphnelo) added to standard therapy significantly improves treatment outcomes in patients with ...

The total market size of systemic lupus erythematosus is expected to increase in the 7MM during the forecast period, driven by ongoing clinical research of therapies such as nipocalimab (Johnson & ...

The JASMINE trial showed nipocalimab's efficacy in SLE, meeting primary and secondary endpoints, including steroid sparing ...

Imaavy will now progress to Phase III in SLE, though it will face strong competition from SLE market leader, Benlysta, if ...

Please provide your email address to receive an email when new articles are posted on . SLE-DAS remission and low disease activity discriminated between patients taking active drug vs. placebo. Both ...

Findings showed a higher percentage of participants on obinutuzumab achieved a minimum 4-point improvement in SRI-4 at 52 weeks vs standard therapy. Topline data were announced from a phase 3 trial ...

Telitacicept, a dual inhibitor of the cytokines B-lymphocyte stimulator and a proliferation-inducing ligand, showed efficacy ...

For starters, she pointed out that standard CAR-T therapy involves a lymphodepletion regimen with cyclophosphamide and ...